Hubungan antara Obesitas, Konsumsi Tinggi Purin, dan Pengobatan terhadap Kadar Asam Urat dengan Penggunaan Allopurinol pada Pasien Hiperurisemia

Ema P. Yunita; Dinar I. Fitriana; Atma Gunawan

doi:10.15416/ijcp.2018.7.1.1

Hubungan antara Obesitas, Konsumsi Tinggi Purin, dan Pengobatan terhadap Kadar Asam Urat dengan Penggunaan Allopurinol pada Pasien Hiperurisemia

Ema P. Yunita, Dinar I. Fitriana, Atma Gunawan

Abstract

Hiperurisemia adalah kondisi ketika kadar asam urat dalam darah melebihi nilai normal. Terdapat banyak faktor yang memengaruhi peningkatan kadar asam urat, seperti obesitas, konsumsi tinggi purin, dan pengobatan. Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara obesitas, konsumsi tinggi purin, dan pengobatan terhadap kadar asam urat dengan penggunaan allopurinol pada pasien hiperurisemia. Data diperoleh melalui rekam medis dan kuesioner dari RSUD Dr. Saiful Anwar, Malang, dan dengan studi potong melintang. Pengambilan sampel dilakukan selama satu bulan (April–Mei 2014). Data dianalisis secara deskriptif dan diuji hipotesis. Sampel penelitian ini adalah 45 pasien hiperurisemia yang memperoleh allopurinol sebagai terapinya selama satu bulan dan pasien dipilih dengan metode pengambilan sampel konsekutif. Hasil dari penelitian ini menunjukkan bahwa tidak terdapat hubungan komparasi yang bermakna secara statistik antara kadar asam urat terhadap obesitas (0,193), konsumsi tinggi purin yaitu makanan laut (0,420), daging (0,469), jerohan (0,054), dan polong-polongan (0,398) juga pengobatan yaitu furosemid (0,631), aspirin dosis rendah (0,773), hidroklorotiazid (0,216), dan spironolakton (0,246). Selain itu, tidak pula terdapat korelasi yang bermakna secara statistik antara kadar asam urat terhadap obesitas (0,197), konsumsi tinggi purin yaitu makanan laut (0,426), daging (0,476), jerohan (0,053), dan polong-polongan (0,404) juga pengobatan yaitu furosemid (0,637), aspirin dosis rendah (0,776), hidroklorotiazid (0,220), dan spironolakton (0,250).

Kata kunci: Allopurinol, asam urat, penghambat xantin oksidase

Associations between Obesity, High Purine Consumptions, and Medications on Uric Acid Level with the Use of Allopurinol in Hyperuricemia Patients

Hyperuricemia is a condition when the blood uric acid level exceeds the normal amount. There are many factors that can increase the uric acid level, such as obesity, high purine consumptions, and medications. The aim of this study was to determine the associations between obesity, high purine consumptions, and medications on uric acid level with the use of allopurinol in hyperuricemia patients. Data were collected through medical records and questionnaires from General Hospital of Dr. Saiful Anwar, Malang, and delivered within a cross-sectional study. Sampling was conducted for one month (April–May 2014). Data were analyzed descriptively and tested hypothetically. The samples of this study were 45 hyperuricemia patients who had gotten allopurinol as their therapy for a month and they were choosen by the consecutive sampling method. The results of this study showed that there were no statistically significant comparative association between uric acid level on obesity (0.193), high purine consumptions i.e. seafoods (0.420), meats (0.469), organ meats (0.054), and pods (0.398) also medications i.e. furosemide (0.631), low dose aspirin (0.773), hydrochlorotiazide (0.216), and spironolactone (0.246). In particular, there were no statistically significant correlations between uric acid level on obesity (0.197), high purine consumptions i.e. seafoods (0.426), meats (0.476), organ meats (0.053), and pods (0.404) also medicines i.e. furosemide (0.637), low dose aspirin (0.776), hydrochlorotiazide (0.220), and spironolactone (0.250).

Keywords: Allopurinol, uric acid, xanthin oxidase inhibitor

Keywords

Allopurinol, asam urat, penghambat xantin oksidase

Full Text:

PDF (Bahasa Indonesia)

References

Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A pathophysiologic approach, 7th Edition. New York: The McGraw-Hill Companies Inc; 2008.

Greene RJ, Harris ND. Pathology and therapeutics for pharmacists: A basis for clinical pharmacy practice, 3rd Edition. London: Pharmaceutical Press; 2008.

Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. J Am Med Assoc. 2008;300(8):924–32. doi: 10.1001/jama.300.8.924.

Lee M. Basic skills in interpreting laboratory data, 4th Edition. Bethesda: American Society of Health-System Pharmacists, Inc; 2009.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh M, Neogi T, et al. 2012 American college of rheumatology guidelines for management of gout part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46. doi: 10.1002/acr.21772

Purwaningsih T. Risk factors of hyperuricemia (case study at Kardinah hospital Tegal) (thesis). Semarang: Universitas Diponegoro; 2009.

Dahlan M. Sample size and sampling. Jakarta: Salemba Medika; 2010.

Chen L, Zhu W, Chen Z, Dai H, Ren J, Chen J, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593–8. doi: 10.1631/jzus.2007.B0593

Shiraishi H, Une H. The effect of the interaction between obesity and drinking on hyperuricemia in japanese male office workers. J Epidemiol. 2009;19(1):12–6. doi: 10.2188/jea.JE20080016

Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47(8):929–33.

Nasrul E, Sofitri. Hyperuricemia in pre-diabetes. Andalas J Health. 2012; 1(2):86 –91.

Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013;14(164):1–9. doi: 10.1186/1471-2369-14-164

Villegas R, Xiang YB, Elasy T, Xu WH, Cai H, Cai Q, et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: The shanghai men’s health study. Nutr Metab Cardiovasc Dis. 2012;22(5):409–16. doi: 10.1016/j.numecd.2010.07.012

Yu KH, See LC, Huang YC, Yang CH, Sun JH. Dietary factors associated with hyperuricemia in adults. Semin Arthritis Rheum. 2008;37(4):243–50. doi: 10.1016/j.semarthrit.2007.04.007

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93. doi: 10.2215/CJN.01580210

Hamburger M, Baraf HS, Adamson TC, Basile J, Bass L, Cole B, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(1):3–6. doi: 10.3810/pgm.2011.11.2511.

Medscape app for Android, WebMD, LLC. Reuters Health Information. 2017.

Bonakdaran S, Hami M, Shakeri MT. Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus. Iran J Kidney Dis. 2011;5(1):21–4.

DOI: https://doi.org/10.15416/ijcp.2018.7.1.1